Bill Wiesler has served as the Director of the Blavatnik Fund for Innovation at Yale since 2017, and as Director of New Ventures at OCR since 2006. In that role, he works with Yale faculty and students to form biotech startups based on Yale technologies. Bill has played a key role in recruiting entrepreneurs and capital in dozens of ventures and has held numerous Board and Observer seats. He currently serves as a Board Observer of IsoPlexis, a company developing a single cell immunoassay device.
Prior to joining OCR, Bill was with McKinsey & Company, where he served senior management at four of the top ten global pharmaceutical companies on a range of strategic and business development issues. Prior to McKinsey, Bill was with Radius Ventures, a startup and early-stage venture capital firm focused on the health and life sciences industry. Earlier, Bill held research positions at Cadus Pharmaceutical Corp., where he headed drug discovery, and at University of Colorado, where he was an American Cancer Society fellow.
He is a summa cum laude graduate of Princeton University, and earned both an M.B.A. and a Ph.D. in Chemistry from Columbia University.